Immunomodulatory activity and effectiveness of macrolides in chronic airway disease.
about
Secretion properties, clearance, and therapy in airway diseaseMultidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense?Successful treatment with erythromycin for idiopathic thrombocytopenic purpuraMicrobiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumoniaWhole-animal chemical screen identifies colistin as a new immunomodulator that targets conserved pathways.Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Mycoplasma pneumoniae and its role in asthmaErythromycin enhances CD4+Foxp3+ regulatory T-cell responses in a rat model of smoke-induced lung inflammation.Pathogen- and host-directed anti-inflammatory activities of macrolide antibioticsChlamydophila pneumoniae and Mycoplasma pneumoniae: a role in asthma pathogenesis?Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease.Plastic bronchitis in an adult with asthma.Macrolide immunomodulatory effects and symptom resolution in acute exacerbation of chronic bronchitis and acute maxillary sinusitis: a focus on clarithromycin.Utility of adjunctive macrolide therapy in treatment of children with asthma: a systematic review and meta-analysisInduction of IL-8 by Mycoplasma pneumoniae membrane in BEAS-2B cells.Novel medications for asthma: a look at the future.Nasal and sinus inflammation in chronic obstructive pulmonary disease.Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjectsTherapies for interstitial lung disease: past, present and future.Bugs and asthma: a different disease?Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.Anti-inflammatory effects of macrolides in childhood lung diseases.Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge.Suppression of oxidant-induced glutathione synthesis by erythromycin in human bronchial epithelial cells.Beta-lactam versus beta- lactam/macrolide therapy in pediatric outpatient pneumonia.Anti-inflammatory effects of antibacterials on human Bronchial epithelial cells.Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients.A comparison of in vitro ADME properties and pharmacokinetics of azithromycin and selected 15-membered ring macrolides in rodents.Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells.Accumulation of azithromycin and roxithromycin in tracheal epithelial fetal cell lines expressing wild type or mutated cystic fibrosis transmembrane conductance regulator protein (CFTR).Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease.
P2860
Q21195704-9978403F-2198-42CF-B2F4-0052A454882CQ27025554-F47B15C3-B5C3-4DC6-A689-10D2AFC584ABQ33396198-416687A3-3FF1-42A9-9DC9-875E5A573156Q33935311-CD95ED5A-5604-428D-AC6C-A3972BAAE4E8Q34093437-50212ED0-8D62-4CF6-B721-3DA5E423A4E5Q34297656-E8441888-2AC1-4C12-B31E-A945E0CCEDADQ34653507-2DFF0B40-2C46-48C1-8B82-9100D645C57AQ36020700-D23FB283-ED97-4045-B611-DBA59C4C28B6Q36072425-88D6A7EE-B001-4862-BBC0-84C5643F64D0Q36165742-46843840-4432-4AD9-8747-AB87FD0082C9Q36379352-E3FADB42-2FB7-4BEE-8ED3-0FFD00A41603Q36380940-CFE30AF3-871D-4638-8D4C-B2F4CCE7B0BDQ36505493-106B5E9B-826F-4A6A-82B5-2A5921F197AFQ36547593-779BC500-D5E6-459C-ACE2-392300EC815EQ36808066-05E320EE-B99D-495E-BD05-A70096C2B5A5Q36821380-1452BAE1-D245-4EE0-81FB-C097500E0E64Q36832384-E01C7F81-5F11-4B8E-8B6C-3320363E9274Q36969875-55FAD3F3-B03F-41E3-A851-37538644F1F2Q37362642-25243973-1529-4088-A6EF-01398F9EF9A3Q37455701-1CD76A5B-CA56-4DBB-AE72-E06A588BC89CQ37959271-EF56F10E-DF42-40EB-B800-9C904E4D9847Q38071534-4D93EA93-6097-43C1-9C3F-3FDD21131CABQ38529613-4212EA0A-AD3F-4440-9763-163CD58CE02FQ40046116-63E2F996-84C4-49EE-84A5-AC75DA7DC43DQ41001680-83AEC14E-9A2A-485F-9FB5-8EC30D465DB2Q42083447-E9C13B20-5642-4870-B160-A7277FF9E759Q44422793-8AC662E7-E052-4E37-8D7E-BA30955A2516Q45718671-88678F64-50CD-4AB3-A080-838A20E5A806Q46639328-DD66144A-A5E2-4739-B9BA-1FACF23CA198Q46707121-4B21621B-33A2-46AF-B1EF-D7DA50950110Q48009990-17AB967A-8826-4AA0-875E-FEC6CC470167
P2860
Immunomodulatory activity and effectiveness of macrolides in chronic airway disease.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Immunomodulatory activity and effectiveness of macrolides in chronic airway disease.
@ast
Immunomodulatory activity and effectiveness of macrolides in chronic airway disease.
@en
type
label
Immunomodulatory activity and effectiveness of macrolides in chronic airway disease.
@ast
Immunomodulatory activity and effectiveness of macrolides in chronic airway disease.
@en
prefLabel
Immunomodulatory activity and effectiveness of macrolides in chronic airway disease.
@ast
Immunomodulatory activity and effectiveness of macrolides in chronic airway disease.
@en
P1433
P1476
Immunomodulatory activity and effectiveness of macrolides in chronic airway disease.
@en
P2093
Bruce K Rubin
Markus O Henke
P304
P356
10.1378/CHEST.125.2_SUPPL.70S
P407
P433
P577
2004-02-01T00:00:00Z